Effect of Taurine on Glycemic Control in Type I and Type II Diabetic Patients

Hamad Medical Corporation (HMC) logo

Hamad Medical Corporation (HMC)

Status and phase

Unknown
Phase 2
Phase 1

Conditions

Because the Body Does Not Produce Enough Insulin,
is Produced.
Which a Person Has High Blood Sugar, Either
or Because Cells do Not Respond to the Insulin That
it is a Group of Metabolic Diseases in

Treatments

Drug: Taurine

Study type

Interventional

Funder types

Industry

Identifiers

NCT01226537
NCT01225588

Details and patient eligibility

About

Diabetes mellitus (DM) and its vascular complications are the one of the most prevalent diseases in the state of Qatar. It is a multifactorial disease associated with the development of retinopathy, nephropathy, neuropathy, cardiomyopathy, and severe vascular dysfunction. The complications of diabetes are caused by either insulin deficiency (type 1 DM) or insulin resistance (type II DM).Unfortunately, effective and sustainable prevention programs of diabetes are limited, and treatment options for type II DM are restricted. Current therapy is based upon control of blood glucose, cholesterol and triglycerides, primarily through insulin replacement in type I diabetes or oral hypoglycemic agents and/or insulin replacement in type II diabetes. New therapies able to prevent vascular complications of diabetes are needed to decrease the occurrence of end organ damage and improve the quality of life of the people. Safe and effective nutritional supplements that could be given along with the regular treatment of the patients that might reduce the need for insulin replacement therapy provide tighter glucose control and protect against oxidative stress and the vascular pathology associated with diabetes mellitus are the need of the hour. Our hypothesis is that supplementation of Taurine in the diets of diabetic patients might reduce the dose or need for insulin replacement therapy and protect them against oxidative stress that is responsible for the complications of diabetes mellitus.

Enrollment

20 estimated patients

Sex

All

Ages

18 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Male or Female
  • Above 18-65 Years of old
  • Known diabetic patients with HbA1c>8.0%
  • People who provide signed informed consent -

Exclusion criteria

1. Pregnancy 2. Diabetic patients with HbA1c <8.0 % 3. Recent or prospective surgical interventions 4. Complications of Type I and Type II DM, e.g., Active cardiovascular disease, nephropathy, retinopathy, neuropathy 5. People who do not provide signed informed consent

Trial design

20 participants in 4 patient groups, including a placebo group

Diabetes Mellitus type 1 taurine
Active Comparator group
Description:
A total of 20 patients with 10 Type I and 10 type II diabetic will be enrolled in the study.After the preliminary examinations, we will categorize 10 Type I and Type II patients into two groups randomly (each group contain 5 patients).500mg Taurine capsules will be given twice per day for 6 months.
Treatment:
Drug: Taurine
Diabetes mellitus type 1 placebo
Placebo Comparator group
Description:
A total of 20 patients with 10 Type I and 10 type II diabetic will be enrolled in the study.After the preliminary examinations, we will categorize 10 Type I and Type II patients into two groups randomly (each group contain 5 patients).500mg Taurine capsules will be given twice per day for 6 months.
Treatment:
Drug: Taurine
Diabetes type 2 taurine
Active Comparator group
Description:
A total of 20 patients with 10 Type I and 10 type II diabetic will be enrolled in the study.After the preliminary examinations, we will categorize 10 Type I and Type II patients into two groups randomly (each group contain 5 patients).500mg Taurine capsules will be given twice per day for 6 months.
Treatment:
Drug: Taurine
Diabetes type 2 placebo
Placebo Comparator group
Description:
A total of 20 patients with 10 Type I and 10 type II diabetic will be enrolled in the study.After the preliminary examinations, we will categorize 10 Type I and Type II patients into two groups randomly (each group contain 5 patients).500mg Taurine capsules will be given twice per day for 6 months.
Treatment:
Drug: Taurine

Trial contacts and locations

0

Loading...

Central trial contact

Yousef Al Ansari, MD; Shajitha Thekkeveetil, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems